Literature DB >> 30178900

The Quality of Working Life Questionnaire for Cancer Survivors: Sufficient responsiveness for use as a patient-reported outcome measurement.

Sietske J Tamminga1, Merel de Jong1, Monique H W Frings-Dresen1, Angela G E M de Boer1.   

Abstract

To assess the responsiveness and interpretability of the Quality of Working Life Questionnaire for Cancer Survivors (QWLQ-CS). A cohort study was conducted in which 130 (self-)employed cancer survivors completed the QWLQ-CS at baseline and 107 at follow-up and six single-item external anchors to measure change. Cancer survivors were diagnosed between 3 months and 10 years previously. To measure responsiveness we assessed the Area Under the Curve (AUC) of Receiver Operation Characteristic (ROC). To assess interpretability we compared Minimal Important Change (MIC) to Smallest Detectable Change at group level (SDC_group). The MIC was based on the mean change method and the SDC on the measurement error. We found sufficient responsiveness for improvement with AUC of 0.72 and sufficient interpretability with MIC (3.9) exceeding the SDC_group (2.8). Accordingly, we found sufficient responsiveness for deterioration with AUC of 0.27 and sufficient interpretability with MIC (-7.4) exceeding SDC_group (2.8). An improvement of 3.9 on the QWLQ-CS is meaningful to cancer survivors as is a deterioration of -7.4, both of which can be reliably measured at group level. The QWLQ-CS can be used as a patient-reported outcome measurement (PROM) of an intervention in research or practice at group level.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer survivors; interpretability; patient-reported outcome measurement; psychometric properties; quality of working life; responsiveness

Mesh:

Year:  2018        PMID: 30178900     DOI: 10.1111/ecc.12910

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  3 in total

1.  The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility.

Authors:  Michiel A Greidanus; Angela G E M de Boer; Angelique E de Rijk; Sonja Brouwers; Theo M de Reijke; Marie José Kersten; Jean H G Klinkenbijl; Roy I Lalisang; Robert Lindeboom; Patricia J Zondervan; Monique H W Frings-Dresen; Sietske J Tamminga
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

2.  The MiLES intervention targeting employers to promote successful return to work of employees with cancer: design of a pilot randomised controlled trial.

Authors:  Michiel A Greidanus; Angela G E M de Boer; Angelique E de Rijk; Monique H W Frings-Dresen; Sietske J Tamminga
Journal:  Trials       Date:  2020-04-28       Impact factor: 2.279

3.  Impaired Quality of Working Life in Inflammatory Bowel Disease Patients.

Authors:  Sara van Gennep; Nanne K H de Boer; Marieke E Gielen; Svend T Rietdijk; Krisztina B Gecse; Cyriel Y Ponsioen; Marjolijn Duijvestein; Geert R D'Haens; Mark Löwenberg; Angela G E M de Boer
Journal:  Dig Dis Sci       Date:  2020-10-16       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.